AI Article Synopsis
- The study investigates the anti-mycobacterial activity of Plumeria bicolor extract and its components, plumericin and isoplumericin, against drug-resistant Mycobacterium tuberculosis, highlighting a pressing need for new treatments due to rising antibiotic resistance.
- Using in vitro methods, the researchers assessed the minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) of these substances, finding plumericin to be significantly more effective than isoplumericin and even outperforming standard drugs like rifampicin and isoniazid.
- The findings suggest that plumericin and isoplumericin have strong potential as new anti-mycobacterial agents without significant toxicity to host cells
Article Abstract
Background And Objectives: Because of the developing resistance of Mycobacterium species against currently available anti-mycobacterial drugs, there is an urgent need for new drug development. In this study, we have evaluated the in vitro anti-mycobacterial activity of Plumeria bicolor extract and its phytoconstituents - plumericin and isoplumericin against multi-drug resistance Mycobacterium tuberculosis.
Methods: The in vitro anti-mycobacterial activity of chloroform extract of P. bicolor, plumericin and isoplumericin were tested against M. tuberculosis (H37Rv) and four multi-drug resistant (MDR) clinical isolates by measuring the minimum inhibitory concentration (MIC) using MTT (Tetrazolium bromide [3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide]) assay. The extract and both compounds were further evaluated by standard assay procedures to determine their minimum bactericidal concentration (MBC). Cytotoxicity of these compounds was performed against J774G8 murine macrophage cell lines. The activity was represented in the mean (±SD) of duplicate samples from three independent assays.
Results: Plumericin showed better activity against pan sensitive as well as four MDR strains of M. tuberculosis with MIC values of 2.1 ± 0.12, 1.3 ± 0.15, 2.0 ± 0.07, 1.5 ± 0.13 & 2.0 ± 0.14 μg/mL and MBC values of 3.6 ± 0.22, 2.5 ± 0.18, 3.8 ± 0.27, 2.9 ± 0.20 & 3.7 ± 0.32 μg/mL than isoplumericin, respectively. Interestingly, both isolated active compounds showed an advantage over rifampicin (80 times) and isoniazid (8 times) by being highly active against the MDR strains. The extract and both compounds were found to be non-toxic against J774G8 macrophages up to the used concentrations.
Conclusion: Plumericin showed more potent activity than isoplumericin. The excellent activity of these compounds against MDR strains opens a possibility of obtaining new anti-mycobacterial drug candidate in near future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pupt.2013.01.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A conserved human CD4+ T cell subset recognizing the mycobacterial adjuvant, trehalose monomycolate.
J Clin Invest
December 2024
Department of Molecular Immunology, Research Institute for Microbial Diseas, Osaka University, Suita, Japan.
Mycobacterium tuberculosis causes human tuberculosis. As mycobacteria are protected by thick lipid cell wall, humans have developed immune responses against diverse mycobacterial lipids. Most of these immunostimulatory lipids are known as adjuvants acting through innate immune receptors, such as C-type lectin receptors.
View Article and Find Full Text PDFAntimycobacterial Activity of Solid Lipid Microparticles Loaded with Ursolic Acid and Oleanolic Acid: In Vitro, In Vivo, and Toxicity Assessments.
Microorganisms
October 2024
Nanobios Lab, Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India.
Article Synopsis
- Ursolic acid (UA) and oleanolic acid (OA) are natural compounds with anti-mycobacterial properties but have poor solubility, limiting their use in treatment.
- Researchers developed solid lipid microparticles (SLMs) to effectively deliver UA and OA, demonstrating their ability to inhibit both drug-sensitive and multidrug-resistant tuberculosis (Mtb) in lab tests.
- In mouse models, the delivery of SLMs via inhalation significantly reduced bacterial loads and improved survival rates without causing toxicity, showcasing their potential as a safe and effective treatment option for tuberculosis.
Antioxidant: Antimycobacterial and Antibiofilm Activities of Acetone Extract and Subfraction Jacq. ex Willd. Against .
Antibiotics (Basel)
October 2024
Department of Biochemistry, Microbiology and Biotechnology, University of Limpopo, Private Bag X1106, Sovena 0727, South Africa.
Tuberculosis is a worldwide prevalent and recurring disease that contributes significantly to high mortality rates. This study aimed to investigate the antioxidant, anti-mycobacterial, and antibiofilm activities of acetone crude extract. The crude acetone extract was fractionated using column chromatography and characterized by liquid chromatography-mass spectroscopy (LC-MS).
View Article and Find Full Text PDFFuramidine-induced autophagy exerts an anti-mycobacterial effect in a SIRT1-pAMPK-FOXO3a-dependent manner by elevation of intracellular Ca level expression.
Microbiol Res
January 2025
Laboratory of Mycobacterial Immunology, Department of Life Science, National Institute of Technology, Rourkela, Odisha 769008, India. Electronic address:
Article Synopsis
- Mycobacterium tuberculosis is a leading cause of global mortality, and to combat it effectively, improvements in diagnostics, drug regimens, and vaccinations are essential.
- The study investigates Furamidine, a compound that may enhance autophagy—a defense mechanism against pathogens—by evaluating its effects on tuberculosis bacteria within human cells.
- Findings demonstrate that Furamidine reduces mycobacterial growth and induces autophagy by affecting intracellular calcium levels and activating specific proteins, suggesting it could be a promising approach to improve TB treatment.
Design, Synthesis, and Anti-Mycobacterial Evaluation of Triclosan-Isoniazid Hybrids.
Chem Biodivers
November 2024
Department of chemistry, Guru Nanak Dev University, Amritsar, Punjab, India.
A series of Triclosan-based hybrids and their Schiff base derivatives with isoniazid were designed through in silico modeling and synthesized using copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction. These compounds were then evaluated against both Mycobacterium tuberculosis (Mtb) and Mycobacterium abscessus (Mab). However, none of the synthesized hybrids exhibited significant growth inhibition, with minimum inhibitory concentration (MIC) values consistently exceeding 100 µg/mL.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!